Rhesus monkey experiments show that: early use of redoxivir has a good effect
Science and Technology Daily, Beijing, June 11 (Reporter Zhang Mengran) A study published on the 10th of the British journal Nature used early treatment with the antiviral drug ridxivir to reduce the viral load in rhesus monkeys infected with the new coronavirus To avoid developing pneumonia. This finding supports the early use of reduxil in the treatment of patients with new coronary pneumonia.
Redoxir has extensive antiviral activity and was originally planned for the treatment of diseases such as Ebola hemorrhagic fever and Middle East respiratory syndrome. The U.S. Food and Drug Administration has previously issued an emergency use authorization that allows American medical institutions to "emergency use" reduxil when treating severe patients with new coronary pneumonia. Therefore, in the current human clinical trials, redoxir is used to treat new coronary pneumonia.
This time, scientists from the National Institute of Allergy and Infectious Diseases affiliated to the National Institutes of Health investigated the therapeutic effect of Ridsivir on the newly established new coronavirus infection model-rhesus monkeys. Two groups of rhesus monkeys (6 in each group) were infected with new coronavirus; one group received Radecivir treatment after 12 hours (near the peak of viral replication in the lungs), and every 6 days after infection Receive treatment every 24 hours.
Compared with the control group, the treatment group showed no signs of respiratory disease, less lung damage, and lower viral load in the lower respiratory tract; 12 hours after receiving the first dose, the virus in the lower respiratory tract The level is about 1% of the control group. Three days after the initial infection, no virus was detected in the treatment group of rhesus monkeys, but 4 of the 6 control rhesus monkeys were still detectable. Although the viral load of the lower respiratory tract has decreased, no decrease in viral excretion has been observed, which means that clinical improvement may not be equivalent to lack of infectivity.
The research team pointed out that the dose of redcivir used in rhesus monkeys is the same as that used in humans. They reminded that it is difficult to directly translate the time of treatment into the corresponding human disease stage, because rhesus monkeys generally produce only mild illnesses. Studies have shown that when using Radecivir for the treatment of new coronary pneumonia, it should be started as early as possible to maximize the therapeutic effect.